AstraZeneca, Daiichi Sankyo eye first approval for TROP2 drug after PhIII breast cancer success

As­traZeneca and Dai­ichi Sankyo’s TROP2-tar­get­ed an­ti­body-drug con­ju­gate has met a key end­point in the Phase III TRO­PI­ON-Breast01 tri­al, bring­ing it one step clos­er to po­ten­tial­ly com­pete against Gilead’s Trodelvy.

TRO­PI­ON-Breast01 is eval­u­at­ing the drug can­di­date, da­to-DXd, against in­ves­ti­ga­tors’ choice of chemother­a­py in 733 pa­tients with pre­vi­ous­ly-treat­ed in­op­er­a­ble or metasta­t­ic HR-pos­i­tive, HER2-neg­a­tive breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.